Sickle-Cell Disease Clinical Trial
Official title:
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).
A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).
This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study
designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days
continuous IV administration of sevuparin for the management of acute VOC in subjects with
SCD.
Adults and adolescents ≥ 12 years of age will be randomized to treatment with sevuparin or
placebo (ratio 1:1).
;